Xerophilusin G exhibits significant potential in pharmaceutical research due to its cytotoxic properties. It has been investigated for its ability to inhibit the growth of certain cancer cell lines, making it a candidate for anticancer drug development. Its mechanism involves inducing apoptosis in tumor cells through disruption of mitochondrial function. Additionally, Xerophilusin G shows moderate antimicrobial activity against select pathogenic strains, suggesting possible use in antimicrobial therapies. Ongoing studies focus on optimizing its bioavailability and reducing off-target effects for therapeutic applications.